Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.

Kearns, Donovan G; Uppal, Shelley; Chat, Vipawee S; Wu, Jashin J

Kearns, Donovan G; Uppal, Shelley; Chat, Vipawee S; Wu, Jashin J.

J Drugs Dermatol ; 20(5): 582-583, 2021 May 01.

Article in English | MEDLINE | ID: covidwho-1212126

Subject(s)

COVID-19/epidemiology; Phosphodiesterase 4 Inhibitors/therapeutic use; Psoriasis/drug therapy; Thalidomide/analogs & derivatives; Anti-Inflammatory Agents, Non-Steroidal/adverse effects; COVID-19/immunology; Clinical Trials, Phase III as Topic/methods; Humans; Phosphodiesterase 4 Inhibitors/adverse effects; Psoriasis/diagnosis; Psoriasis/immunology; Risk Factors; Thalidomide/adverse effects; Thalidomide/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / Thalidomide / Phosphodiesterase 4 Inhibitors / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: J Drugs Dermatol Journal subject: Dermatology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google